Home > Market Research > Prescription Medicines > Immunotherapy of Cancer

Table of Contents

Market Study
Published: February 2007
Pages: 193
Tables: 47
From: GBP 3031.00   Buy Now!
Research from: Business Communications Company Inc.
Sector: Prescription Medicines

REPORT HIGHLIGHTS
The global market for immunotherapies to treat cancer was worth $19.6 billion in 2006 and will reach $23.7 billion by the end of 2007. At a compound annual growth rate (CAGR) of 9.5%, the global market will be worth more than $37.2 billion by 2012.
Monoclonal cancer treatments have the largest share of the global market. In 2006 they were worth more than $10.4 billion and will reach more than $16.1 billion by 2012, a CAGR of 6.2%
Cancer vaccines have the greatest potential for growth, growing at a CAGR of 35.2% to reach more than $5.4 billion by 2012.

INTRODUCTION
Cancer immunotherapeutics, in particular monoclonal antibody-based products and vaccines, are transforming the cancer treatment market and providing a whole new arsenal of weapons. The introduction of the first monoclonal antibody product to the worldwide market for the treatment of cancer in 1998 initiated a cascade of additional monoclonal antibody products for the treatment of cancer that continues unabated. Average annual growth of monoclonal antibody products has stayed in the double digits since the late 1990s. In 2006, antibodies were the single largest class of therapeutics in clinical development with the exception of vaccines. Essentially every biotech and pharmaceutical company, large or small, has a research program that centers on monoclonal antibodies.
The first dedicated off-the-shelf (not patient-specific) cancer vaccine was introduced to the market in 2006. Merck's Gardasil (quadrivalent human papillomavirus recombinant vaccine) was approved by the FDA in June 2006 for the prevention of cervical cancer associated with human papillomavirus (HPV). The approval of Gardasil marks the first time the FDA approved a designated therapeutic cancer vaccine. Gardasil was approved in the E.U. in September 2006. This report discusses the impact of these new and growing classes of cancer drugs, their influence on the market in terms of treatment and revenues, and how they will complement and/or compete with existing products.
The information and analysis presented in this report on cancer immunotherapy products are important assets in decision-making for managers involved in business development, marketing, market research, product development, mergers and acquisitions, licensing, business management, investment banking and for consultants to the pharmaceutical and biotechnology industries. The study provides a comprehensive analysis of the current markets for cancer immunotherapy products and, in particular, the market potential of promising drugs, vaccines and technologies under development.
SCOPE OF STUDY
This report contains:
Analyses of products and applications in the cancer immunotherapy sector, including biological response modifiers (cytokines), monoclonal antibody-based products, therapeutic vaccines and other cancer immunotherapies.
An overview of the global market, including historical data for cancer treatment and therapies, the latest market trends, and 5-year forecasts and estimates through 2012
A section on industry structure with strategies employed by Big Pharma as well as top-selling drug patent expirations and how this relates to the overall pharmaceutical industry and biotechnology companies in particular
Sections on products and applications with synopses of more than 100 cancer immunotherapy drug and vaccine products, including those currently marketed and those in Phase III or later development
Analyses of patents within the past few decades
Profiles for important businesses.
METHODOLOGY
The base year for this study is 2006. Figures are based on revenue figures at the manufacturers' level and are projected at 2006 dollar value; that is, inflation is not computed into the projection figures.
This study was prepared from information obtained from product managers, marketing strategists, research executives and others at leading pharmaceutical and biotechnology companies that compete in the market for cancer immunotherapeutics or which have products in development for this market.
INFORMATION SOURCES
The information and analyses presented in this report are based on an extensive survey of the biotechnology and pharmaceutical industries as well as a detailed examination of published literature and reports obtained from regulatory authorities, medical research institutions, pharmaceutical trade associations and national and world health organizations. Key information from the business literature was used as to obtain expert opinion on commercial potential and market sizes from industry professionals.

Top of Page

Table of Contents

INTRODUCTION
CONTRIBUTION OF THE STUDY AND FOR WHOM
OBJECTIVES AND GOALS OF THE STUDY
STUDY SCOPE AND FORMAT
METHODOLOGY
INFORMATION SOURCES
AUTHOR’S CREDENTIALS
RELATED BCC WORK CREDENTIALS INCLUDING WORK DONE
BY OTHER AUTHORS
BCC ONLINE SERVICES
DISCLAIMER
EXECUTIVE SUMMARY
SUMMARY TABLE GLOBAL MARKET FORECAST FOR
IMMUNOTHERAPIES TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
SUMMARY FIGURE GLOBAL MARKET FORECAST FOR
IMMUNOTHERAPIES TO TREAT CANCER, 2005-2012 ($ MILLIONS)
OVERVIEW
DEFINITION AND ETIOLOGY OF Cancer
CANCER STATISTICS
TABLE 1 PROBABILITY OF DEVELOPING SELECTED INVASIVE CANCERS, BY SEX, BASED ON CANCER CASES DIAGNOSED IN 2000 AND 2002 (%)
TABLE 2 INCIDENCE, MORTALITY AND SURVIVAL RATES FOR COMMON CANCERS IN THE U.S., 2006
TABLE 3 CANCER PREVALENCE RATES IN THE U.S., 2003*
TABLE 3 (CONTINUED)
IMMUNOTHERAPY OF CANCER
TYPES OF CANCER FOR WHICH IMMUNOTHERAPY
TREATMENTS EXIST OR ARE LIKELY TO BE INTRODUCED BY 2012
BREAST CANCER
COLORECTAL CANCER
HEAD AND NECK CANCER
KIDNEY CANCER
LEUKEMIAS
Leukemias (Continued)
LIVER CANCER
LUNG CANCER
MALIGNANT MELANOMA
MULTIPLE MYELOMA
NONHODGKIN’S LYMPHOMA
OSTEOSARCOMA
OVARIAN CANCER
PANCREATIC CANCER
PROSTATE CANCER
STOMACH CANCER
CURRENT METHODS OF TREATMENT
SURGERY
RADIATION THERAPY
PHARMACEUTICAL THERAPY
IMMUNOTHERAPY
INFLAMMATORY RESPONSE
Cell-Mediated Immunity
Humoral Immunity
Macrophage Processing
Nonspecific Immunity
CYTOKINES
Two Types of Cytokines
MONOCYTES
PHAGOCYTES
SPECIFIC IMMUNITY
Lymphocytes
B-Cells
T-Cells
NK Cells
CLINICAL APPROACHES TO IMMUNOTHERAPY
Passive Cellular Immunotherapy
Dealing with Significant Toxicity
Passive Humoral Immunotherapy
Active Specific Immunotherapy
Nonspecific Immunotherapy
TYPES OF IMMUNOTHERAPY PRODUCTS
Biological Response Modifiers
TABLE 4 COLONY STIMULATING FACTORS AND ERYTHROPOIETIN, THEIR NATURAL SOURCES AND MAJOR EFFECTS
TABLE 5 INTERFERONS, THEIR NATURAL SOURCES AND MAJOR EFFECTS
TABLE 6 INTERLEUKINS, THEIR NATURAL SOURCES AND MAJOR EFFECTS
TABLE 6 (CONTINUED)
TABLE 7 TUMOR NECROSIS FACTORS, THEIR NATURAL SOURCES, AND MAJOR EFFECTS
Colony Stimulating Factors
Treating Neutropenic Fevers
A Justified Expense
Interferons
A Family of Small Proteins
Anticancer Effects
Side Effects
Production of Interferon
Interferon-alpha
Interferon-beta
Interferon-Beta-1a
Interleukins
Interleukin-2
Other Infection-Fighting Cells
Side Effects
Tumor Necrosis Factor
ANTIBODIES
ANTIBODY FORMS IN PRODUCTS
Abtides
Antibody Conjugates
Antiserums
Bispecific Antibodies
Camouflaged Antibodies
Chimeric Antibodies
Humanized Antibodies
Fully Human Antibodies
Progenitor Stem Cells
Single-Chain Antibodies
Synthetic Antibodies
VACCINES
ANTIGENS: THEIR ROLE IN CANCER VACCINES
VACCINE DEVELOPMENT STRATEGIES
A SUMMARY OF TWO APPROACHES: LOW-TECH VS. HIGHTECH
TECHNOLOGY ADVANCES
PRODUCTS AND APPLICATIONS
IMMUNOTHERAPY PRODUCTS FOR THE TREATMENT OF CANCER INTRODUCED IN 2004, 2005 AND 2006
TABLE 8 IMMUNOTHERAPY PRODUCTS FOR THE TREATMENT OF CANCER INTRODUCED IN 2004, 2005 AND 2006
MECHANISM OF ACTION OF SELECTED IMMUNOTHERAPY PRODUCTS
TABLE 9 MOLECULAR TARGET(S), MECHANISM(S) OF ACTION AND CANCER(S) TARGETED BY LEADING IMMUNOTHERAPY PRODUCTS
BIOLOGICAL RESPONSE MODIFIERS
THE MARKET FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER
TABLE 10 GLOBAL MARKET FORECAST FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
FIGURE 1 GLOBAL MARKET FORECAST FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER, 2005-2012 ($ MILLIONS)
COLONY STIMULATING FACTORS
MARKETED BRM PRODUCTS FOR THE TREATMENT OF CANCER
TABLE 11 COLONY-STIMULATING FACTOR PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER
Aranesp
Granocyte
Leukine
Neorecormon
Neulasta/Neupopeg/Neupogen/Granulokine
Neumega
Procrit
Stemgen
The Market for Colony Stimulating Factors
TABLE 12 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS IN CANCER TREATMENT BY PRODUCT, THROUGH 2012 ($ MILLIONS)
The Market for Colony Stimulating Factors to Treat
Cancer
TABLE 13 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
FIGURE 2 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
Colony Stimulating Factors in Development
INTERFERONS
Interferon-Alpha
Interferon Alpha-2b Products
Marketed Interferon Products for the Treatment of
Cancer
TABLE 14 INTERFERON PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER
Infergen
Intron A and PEG-Intron/Rebetron
PEG-Intron vs. Intron A
Multiferon
Roferon-A
Interferon-Gamma
Actimmune/Imukin
The Market for Interferon Products Used in the
Treatment of Cancer
TABLE 15 GLOBAL MARKET FORECAST FOR INTERFERON ALPHA AND GAMMA PRODUCTS* USED IN THE TREATMENT OF CANCER BY PRODUCT, THROUGH 2012 ($ MILLIONS)
THE MARKET FOR INTERFERONS TO TREAT CANCER
TABLE 16 GLOBAL MARKET FORECAST FOR INTERFERONS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
FIGURE 3 GLOBAL MARKET FORECAST FOR INTERFERONS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
INTERLEUKINS
Marketed Interleukin Products for the Treatment of
Cancer
TABLE 17 INTERLEUKIN PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER
ONTAK
PROLEUKIN
The Market for Interleukin Products for the Treatment of
Cancer
TABLE 18 GLOBAL MARKET FORECAST FOR INTERLEUKINS IN THE TREATMENT OF CANCER, BY PRODUCT, THROUGH 2012 ($ MILLIONS)
Product
TUMOR NECROSIS FACTOR INHIBITORS
BIOLOGICAL RESPONSE MODIFIERS IN DEVELOPMENT FOR THE TREAMENT OF CANCER
TABLE 19 SELECTED BIOLOGICAL RESPONSE MODIFIERS IN PHASE III OR LATER DEVELOPMENT
Actimmune
Cintrekedin Besudotox
Multikine
Clinical Trial Results
A Coca-Cola Formula
PEG-Intron
PRX321
Virulizin
COMBINATION CYTOKINE-ANTIBODY TECHNOLOGY IN DEVELOPMENT
MONOCLONAL ANTIBODY PRODUCTS
TABLE 20 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER: U.S.
TABLE 20 (CONTINUED)
MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER
Avastin
Avastin (Continued)
Avastin (Continued)
The Avastin Advantage
Medicare Reimbursement Law Supports Use of
Avastin
Bexxar
Bexxar (Continued)
Campath/MabCampath
Erbitux
TABLE 21 RANGE OF EGFR EXPRESSION IN SOLID TUMORS
TABLE 22 EGFR IN PROGNOSIS FOR SELECTED TUMOR TYPES
Erbitux (Continued)
Herceptin
Mylotarg
Panorex
Rituxan/MabThera
Rituxan/Mabthera (Continued)
Vectibix
Zevalin
First Radioimmunotherapeutic Drug
Results of Trials
Sales of Zevalin
THE MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR ALL INDICATIONS
Monoclonal Antibody Sales by Technology
TABLE 23 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY, THROUGH 2012 ($ MILLIONS)
FIGURE 4 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY, 2005-2012 ($ MILLIONS)
Monoclonal Antibody Sales by Target
TABLE 24 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TARGET, THROUGH 2012 ($ MILLIONS)
THE MARKET FOR THERAPEUTIC MONOCLONAL
ANTIBODIES TO TREAT CANCER
TABLE 25 GLOBAL MARKET FORECAST FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, THROUGH 2012 ($ MILLIONS)
TABLE 25 (CONTINUED)
THE EUROPEAN MARKET FOR THERAPEUTIC
MONOCLONAL ANTIBODIES
TABLE 26 MONOCLONAL ANTIBODY PRODUCTS ON THE EUROPEAN MARKET FOR THE TREATMENT OF CANCER
TABLE 27 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, THROUGH 2012 ($ MILLIONS)
FIGURE 5 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, 2005-2012 ($ MILLIONS)
MONOCLONAL ANTIBODY PRODUCTS IN DEVELOPMENT
FOR THE treatment of cancer
TABLE 28 SELECTED MONOCLONAL ANTIBODY PRODUCTS IN PHASE III OR LATER DEVELOPMENT FOR THE TREATMENT OF CANCER
TABLE 28 (CONTINUED)
TABLE 28 (CONTINUED)
Abegrin (formerly Vitaxin)
Avastin
Campath/MabCampath
CP-675,206
Denosumab
Herceptin
HuMax-CD4
HuMax-CD20
HuMax-EGFr
MDX-010
Nimotuzumab
OvaRex
Pemtumomab
Rencarex
Rituxan/MabThera
VACCINES
TABLE 29 TUMOR ANTIGENS USED IN CANCER VACCINES
TYPES OF CANCER VACCINES
Whole-cell Vaccines
Antigen/Adjuvant Vaccines
Idiotype Vaccines
Autologous versus Allogenic Vaccines
Dendritic Cell Vaccines
Synthetic Cell Protein Antigens
Gangliosides
Heat Shock Proteins
CANCER VACCINES ON THE WORLDWIDE MARKET
Gardasil
M-Vax
Melacine
OncoVax
THE MARKET FOR CANCER VACCINES
TABLE 30 ESTIMATED U.S. MARKET FOR CANCER VACCINES BY INDICATION
TABLE 31 GLOBAL MARKET FORECAST FOR CANCER VACCINES, BY TECHNOLOGY, THROUGH 2012 ($ MILLIONS)
FIGURE 6 PERCENTAGE OF GLOBAL MARKET HELD BY AUTOLOGOUS VERSUS ALLOGENEIC CANCER VACCINES, 2007 AND 2012 (%)
CANCER VACCINES IN DEVELOPMENT
TABLE 32 SELECTED CANCER VACCINES IN PHASE III OR LATER TRIALS
TABLE 32 (CONTINUED)
TABLE 33 TYPES OF VACCINES IN DEVELOPMENT FOR CANCER TREATMENT
Allovectin-7
Allovectin-7 (Continued)
BiovaxID
Cervarix
DCVax-Brain
DCVax-Prostate
GMK
GVAX Prostate Vaccine
IGN101
Insegia
Insegia (Continued)
Insegia (Continued)
M-Vax
Melacine
MyVax Personalized Immunotherapy
Myvax Personalized ? (Continued)
Oncophage
OncoVax
Panvac-VF
Sipuleucel-T
Stimuvax
TG 4001
TG 1042
Theratope
OTHER IMMUNOTHERAPY PRODUCTS FOR THE TREATMENT OF CANCER
MARKETED PRODUCTS
Gleevec
Iressa
Nexavar
Revlimid
Sprycel
Sutent
Tarceva
Thalomid
Velcade
The Market for Other Immunotherapy Products for the
Treatment of Cancer
TABLE 34 GLOBAL MARKET FORECAST FOR OTHER CANCER TREATMENT IMMUNOTHERAPY PRODUCTS, THROUGH 2012 ($ MILLIONS)
PRODUCTS IN DEVELOPMENT FOR THE TREATMENT OF CANCER
TABLE 35 OTHER IMMUNOTHERPAY PRODUCTS IN PHASE III OR LATER DEVELOPMENT FOR THE TREATMENT OF CANCER
TABLE 28 (CONTINUED)
TABLE 28 (CONTINUED)
Advexin
BAY 43-9006
Ceplene
Dacogen
Efaproxyn
Genasense
Hycamptin
INGN 241
Junovan
Nexavar
Onconase
Orathecin
Pixantrone
PTK787
Telcyta
Thymitaq
Torisel
Tykerb/Tycerb
Velcade
Zarnestra
Zarnestra (Continued)
INDUSTRY
BLOCKBUSTER DRUGS ON THE WORLDWIDE
PHARMACEUTICAL MARKET APPROACH 100
U.S. PHARMACEUTICAL INDUSTRY GROWTH TO INCREASE SLIGHTLY
MORE MERGERS, ACQUISITIONS AND LICENSING
MORE MERGERS, ACQUISITIONS AND ? (Continued)
BIOGENERICS?THE NEXT REVOLUTION
BIOGENERICS?THE NEXT ? (Continued)
COMPANY PROFILES
ABGENIX, INC.
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
XenoMouse and XenoMax Technologies
Technology Advantages
Technology Advantages (Continued)
CORPORATE STRATEGY
ALFACELL CORPORATION
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
CORPORATE STRATEGY
AMGEN, INC.
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
TABLE 36 AMGEN’S PRODUCTS IN PHASE II OR LATER DEVELOPMENT
CORPORATE STRATEGY
ANTIGENICS INC
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
TABLE 37 ANTIGENICS’ PRODUCT PIPELINE
CORPORATE STRATEGY
AVAX TECHNOLOGIES, INC
BUSINESS OVERVIEW
PRODUCTS
CORPORATE STRATEGY
BIOGEN IDEC, INC
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
CORPORATE STRATEGY
BIOMIRA INC
EDMONTON R&D PARK
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
CORPORATE STRATEGY
CHIRON CORPORATION
BUSINESS OVERVIEW
FINANCIAL INFORMATION
LEADING PRODUCTS
CORPORATE STRATEGY
GENENTECH, INC.
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
CORPORATE STRATEGY
TABLE 38 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
TABLE 38 (CONTINUED)
TABLE 39 SELECTED ADDITIONAL PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
GENMAB A/S
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
CORPORATE STRATEGY
GENZYME CORPORATION
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
CORPORATE STRATEGY
GLAXOSMITHKLINE PLC
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
IMCLONE SYSTEMS, INC
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
TABLE 40 IMCLONE SYSTEMS’ PRODUCT PIPELINE
CORPORATE STRATEGY
IMMUNOMEDICS, INC
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
TABLE 41 IMMUNOMEDICS’ THERAPEUTIC PRODUCT PIPELINE
TABLE 41 (CONTINUED)
CORPORATE STRATEGY
MEDAREX, INC.
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
TABLE 42 MEDAREX’S PRODUCT PIPELINE
CORPORATE STRATEGY
MEDIMMUNE, INC.
BUSINESS OVERVIEW
FINANCIAL INFORMATION
LEADING PRODUCTS
Leading Products (Continued)
TABLE 43 MEDIMMUNE’S PRODUCTS IN PHASE II OR LATER DEVELOPMENT
CORPORATE STRATEGY
MERCK & COMPANY, INC
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
CORPORATE STRATEGY
MILLENNIUM PHARMACEUTICALS, INC
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
TABLE 44 MILLENNIUM’S PRODUCTS IN PHASE II OR LATER DEVELOPMENT
CORPORATE STRATEGY
NORTHWEST BIOTHERAPEUTICS, INC
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
TABLE 45 NORTHWEST BIOTHERAPEUTICS’ PRODUCT PIPELINE
CORPORATE STRATEGY
PFIZER CORPORATION
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
CORPORATE STRATEGY
Corporate Strategy (Continued)
PROGENICS PHARMACEUTICALS, INC.
BUSINESS OVERVIEW
FINANCIAL INFORMATION
LEADING PRODUCTS
TABLE 46 PROGENICS’ PRODUCT PIPELINE
CORPORATE STRATEGY
PROTEIN DESIGN LABS
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
TABLE 47 PROTEIN DESIGN LABS’ PRODUCTS IN PHASE II OR LATER
CORPORATE STRATEGY
TRANSGENE S/A
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
CORPORATE STRATEGY
VIREXX MEDICAL CORPORATION
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
CORPORATE STRATEGY
LIST OF TABLES
SUMMARY TABLE GLOBAL MARKET FORECAST FOR IMMUNOTHERAPIES TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
TABLE 1 PROBABILITY OF DEVELOPING SELECTED INVASIVE CANCERS, BY SEX, BASED ON CANCER CASES DIAGNOSED IN 2000 AND 2002 (%)
TABLE 2 INCIDENCE, MORTALITY AND SURVIVAL RATES FOR COMMON CANCERS IN THE U.S., 2006
TABLE 3 CANCER PREVALENCE RATES IN THE U.S., 2003*
TABLE 4 COLONY STIMULATING FACTORS AND ERYTHROPOIETIN, THEIR NATURAL SOURCES AND MAJOR EFFECTS
TABLE 5 INTERFERONS, THEIR NATURAL SOURCES AND MAJOR EFFECTS
TABLE 6 INTERLEUKINS, THEIR NATURAL SOURCES AND MAJOR EFFECTS
TABLE 7 TUMOR NECROSIS FACTORS, THEIR NATURAL SOURCES, AND MAJOR EFFECTS
TABLE 8 IMMUNOTHERAPY PRODUCTS FOR THE TREATMENT OF CANCER INTRODUCED IN 2004, 2005 AND 2006
TABLE 9 MOLECULAR TARGET(S), MECHANISM(S) OF ACTION AND CANCER(S) TARGETED BY LEADING IMMUNOTHERAPY PRODUCTS
TABLE 10 GLOBAL MARKET FORECAST FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
TABLE 11 COLONY-STIMULATING FACTOR PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER
TABLE 12 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS IN CANCER TREATMENTBY PRODUCT, THROUGH 2012 ($ MILLIONS)
TABLE 13 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
TABLE 14 INTERFERON PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER
TABLE 15 GLOBAL MARKET FORECAST FOR INTERFERON ALPHA AND GAMMA PRODUCTS* USED IN THE TREATMENT OF CANCER BY PRODUCT, THROUGH 2012 ($ MILLIONS)
TABLE 16 GLOBAL MARKET FORECAST FOR INTERFERONS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
TABLE 17 INTERLEUKIN PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER
TABLE 18 GLOBAL MARKET FORECAST FOR INTERLEUKINS IN THE TREATMENT OF CANCER, BY PRODUCT, THROUGH 2012 ($ MILLIONS)
TABLE 19 SELECTED BIOLOGICAL RESPONSE MODIFIERS IN PHASE III OR LATER DEVELOPMENT
TABLE 20 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER: U.S.
TABLE 21 RANGE OF EGFR EXPRESSION IN SOLID TUMORS
TABLE 22 EGFR IN PROGNOSIS FOR SELECTED TUMOR TYPES
TABLE 23 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY, THROUGH 2012 ($ MILLIONS)
TABLE 24 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TARGET, THROUGH 2012 ($ MILLIONS)
TABLE 25 GLOBAL MARKET FORECAST FOR MONOCLONAL
ANTIBODY PRODUCTS FOR CANCER TREATMENT, THROUGH 2012 ($ MILLIONS)
TABLE 26 MONOCLONAL ANTIBODY PRODUCTS ON THE EUROPEAN MARKET FOR THE TREATMENT OF CANCER
TABLE 27 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, THROUGH 2012 ($ MILLIONS)
TABLE 28 SELECTED MONOCLONAL ANTIBODY PRODUCTS IN PHASE III OR LATER DEVELOPMENT FOR THE TREATMENT OF CANCER
TABLE 29 TUMOR ANTIGENS USED IN CANCER VACCINES
TABLE 30 ESTIMATED U.S. MARKET FOR CANCER VACCINES BY INDICATION
TABLE 31 GLOBAL MARKET FORECAST FOR CANCER VACCINES, BY TECHNOLOGY, THROUGH 2012 ($ MILLIONS)
TABLE 32 SELECTED CANCER VACCINES IN PHASE III OR LATER TRIALS
TABLE 33 TYPES OF VACCINES IN DEVELOPMENT FOR CANCER TREATMENT
TABLE 34 GLOBAL MARKET FORECAST FOR OTHER CANCER
TREATMENT IMMUNOTHERAPY PRODUCTS, THROUGH 2012 ($ MILLIONS)
TABLE 35 OTHER IMMUNOTHERPAY PRODUCTS IN PHASE III OR LATER DEVELOPMENT FOR THE TREATMENT OF CANCER
TABLE 36 AMGEN’S PRODUCTS IN PHASE II OR LATER DEVELOPMENT
TABLE 37 ANTIGENICS’ PRODUCT PIPELINE
TABLE 38 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
TABLE 39 SELECTED ADDITIONAL PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
TABLE 40 IMCLONE SYSTEMS’ PRODUCT PIPELINE
TABLE 41 IMMUNOMEDICS’ THERAPEUTIC PRODUCT PIPELINE
TABLE 42 MEDAREX’S PRODUCT PIPELINE
TABLE 43 MEDIMMUNE’S PRODUCTS IN PHASE II OR LATER DEVELOPMENT
TABLE 44 MILLENNIUM’S PRODUCTS IN PHASE II OR LATER DEVELOPMENT
TABLE 45 NORTHWEST BIOTHERAPEUTICS’ PRODUCT PIPELINE
TABLE 46 PROGENICS’ PRODUCT PIPELINE
TABLE 47 PROTEIN DESIGN LABS’ PRODUCTS IN PHASE II OR LATER
LIST OF FIGURES
SUMMARY FIGURE GLOBAL MARKET FORECAST FOR IMMUNOTHERAPIES TO TREAT CANCER, 2005-2012 ($ MILLIONS)
FIGURE 1 GLOBAL MARKET FORECAST FOR BIOLOGICAL
RESPONSE MODIFIERS TO TREAT CANCER, 2005-2012 ($ MILLIONS)
FIGURE 2 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
FIGURE 3 GLOBAL MARKET FORECAST FOR INTERFERONS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
FIGURE 4 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY, 2005-2012 ($ MILLIONS)
FIGURE 5 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, 2005-2012 ($ MILLIONS)
FIGURE 6 PERCENTAGE OF GLOBAL MARKET HELD BY
AUTOLOGOUS VERSUS ALLOGENEIC CANCER VACCINES, 2007 AND 2012 (%)

For full details, please email keithw@cmsinfo.com

Top of Page

Buy now!

Single user PDF

 GBP 3031.00   

PDF Site Licence

 GBP 3718.75   

PDF Enterprise Licence

 GBP 5312.50   

Paper

 GBP 3031.25   

Your personal guarantee

Top of Page